[(E)-3-(4-Bromo-phenyl)-allyloxy]-tert-butyl-dimethyl-silane | 202645-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(E)-3-(4-Bromo-phenyl)-allyloxy]-tert-butyl-dimethyl-silane
• 英文别名: (E)-[3-(4-bromo-phenyl)-allyloxy]-tert-butyldimethylsilane；[(E)-3-(4-bromophenyl)prop-2-enoxy]-tert-butyl-dimethylsilane
• CAS: 202645-43-0
• 化学式: C₁₅H₂₃BrOSi
• 分子量: 327.337
• InChiKey: KTWUPNKRIMRTDG-VOTSOKGWSA-N

物化性质

• 沸点：
  347.5±30.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.48
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [(E)-3-(4-Bromo-phenyl)-allyloxy]-tert-butyl-dimethyl-silane 在 copper(I) bromide dimethylsulfide complex 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 吡啶 为溶剂， 反应 9.0h， 生成 3-{3-[4-((E)-3-Hydroxy-propenyl)-phenoxy]-4-methoxy-phenyl}-propionic acid ethyl ester
  参考文献：
  名称：

  Total Synthesis of Combretastatins D

  摘要：

  The 15-membered caffrane ring of the natural product group of combretastatins D is synthesized in high yield with suitably functionalized saturated seco acids. The key step is a Mitsunobu-type macrolactonization. A common synthon is used for the construction of both combretastatins. The synthesis of combretastatin D-2 is completed by the use of Sammuelson's dehydroxylation protocol, The asymmetric epoxide of combretastatin D-1 is constructed in two separate operations: one asymmetric center is fixed at an early stage of the synthetic route by Sharpless AD of a trans-styrene derivative, inducing the intramolecular formation of the asymmetric epoxide at the final stages. The synthesis of the title compounds is accomplished in high overall yields (37% for D-1 and 41% for D-2, 9 steps in both cases). X-ray crystallographic analysis of the (S)-(+) acetylmandelic ester of (-)-combretastatin D-1 verified its revised structure.

  DOI：

  10.1002/(sici)1521-3765(199801)4:1<33::aid-chem33>3.0.co;2-8
• 作为产物：
  描述：

  反式-4-溴肉桂酸乙酯 在 咪唑 、 二异丁基氢化铝 作用下， 以 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.17h， 生成 [(E)-3-(4-Bromo-phenyl)-allyloxy]-tert-butyl-dimethyl-silane
  参考文献：
  名称：

  Total Synthesis of Combretastatins D

  摘要：

  The 15-membered caffrane ring of the natural product group of combretastatins D is synthesized in high yield with suitably functionalized saturated seco acids. The key step is a Mitsunobu-type macrolactonization. A common synthon is used for the construction of both combretastatins. The synthesis of combretastatin D-2 is completed by the use of Sammuelson's dehydroxylation protocol, The asymmetric epoxide of combretastatin D-1 is constructed in two separate operations: one asymmetric center is fixed at an early stage of the synthetic route by Sharpless AD of a trans-styrene derivative, inducing the intramolecular formation of the asymmetric epoxide at the final stages. The synthesis of the title compounds is accomplished in high overall yields (37% for D-1 and 41% for D-2, 9 steps in both cases). X-ray crystallographic analysis of the (S)-(+) acetylmandelic ester of (-)-combretastatin D-1 verified its revised structure.

  DOI：

  10.1002/(sici)1521-3765(199801)4:1<33::aid-chem33>3.0.co;2-8

文献信息

• New Strategic Reactions for Organic Synthesis:  Catalytic Asymmetric C−H Activation α to Oxygen as a Surrogate to the Aldol Reaction
  作者：Huw M. L. Davies、Rohan E. J. Beckwith、Evan G. Antoulinakis、Qihui Jin

  DOI：10.1021/jo034533c

  日期：2003.8.1

  The C-H activation of silyl ethers by means of rhodium carbenoid-induced C-H insertion represents a very direct method for the stereoselective synthesis of silyl-protected beta-hydroxy esters. The reaction can proceed with very high regio-, diastereo-, and enantioselectivity and represents a surrogate to the aldol reaction. The reaction is catalyzed by the rhodium prolinate complex Rh(2)(S-DOSP)(4)

  借助于铑类胡萝卜素诱导的CH插入而实现的甲硅烷基醚的CH活化代表了一种立体选择性合成甲硅烷基保护的β-羟基酯的非常直接的方法。该反应可以以非常高的区域，非对映和对映选择性进行，并且代表了醛醇缩合反应的替代物。反应由脯氨酸铑络合物Rh（2）（S-DOSP）（4）催化。高化学选择性的关键要求是使用供体/受体取代的类胡萝卜素，例如衍生自芳基重氮乙酸甲酯的那些。可以使用多种甲硅烷基醚，例如烯丙基甲硅烷基醚，四烷氧基硅烷，甚至简单的三甲基甲硅烷基烷基醚。通常，CH活化优先发生在亚甲基位置，因为反应性受空间和电子效应之间的微妙平衡控制。
• Compounds, their preparation and use
  申请人：——

  公开号：US20030195200A1

  公开（公告）日：2003-10-16

  The present invention relates to compounds of the general formula (I) 1 The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及一般式(I)的化合物，这些化合物在治疗和/或预防由核受体介导的疾病方面具有用处，特别是过氧化物酶体增殖物激活受体（PPAR）。